Gilead engaged Milliman to study changes in pricing of protected class drugs in recent years relative to other classes.

This report replicates portions of the 2015 U.S. Government Accountability Office 340B report (a comparison of the per Medicare beneficiary hospital pharmacy outpatient drug spending at 340B hospitals and non-340B hospitals) on a commercially insured population to determine if the relationships found in the Medicare population existed in the commercial markets.

An analysis of 2014 Part D plan profitability to determine if specific pharmacy channels are associated with members that may be more or less profitable for a Medicare Part D carrier.

What are the current costs and future cost trends for specialty drugs?